Mirati Therapeutics Stock Forecast, Price & News

-2.20 (-1.38 %)
(As of 07/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume272,985 shs
Average Volume640,067 shs
Market Capitalization$8.08 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Mirati Therapeutics logo

About Mirati Therapeutics

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.24 out of 5 stars

Medical Sector

963rd out of 2,215 stocks

Pharmaceutical Preparations Industry

464th out of 867 stocks

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions

Is Mirati Therapeutics a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Mirati Therapeutics stock.
View analyst ratings for Mirati Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Mirati Therapeutics?

Wall Street analysts have given Mirati Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mirati Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Mirati Therapeutics?

Mirati Therapeutics saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 3,440,000 shares, a decline of 28.0% from the June 15th total of 4,780,000 shares. Based on an average daily trading volume, of 594,300 shares, the short-interest ratio is currently 5.8 days. Currently, 7.1% of the shares of the stock are short sold.
View Mirati Therapeutics' Short Interest

When is Mirati Therapeutics' next earnings date?

Mirati Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Mirati Therapeutics

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($2.67) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.13) by $0.54. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.17 million. The business's quarterly revenue was down 96.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.02) earnings per share.
View Mirati Therapeutics' earnings history

How has Mirati Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Mirati Therapeutics' stock was trading at $77.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MRTX shares have increased by 103.1% and is now trading at $157.13.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MRTX?

15 analysts have issued 1-year price objectives for Mirati Therapeutics' stock. Their forecasts range from $160.00 to $285.00. On average, they anticipate Mirati Therapeutics' share price to reach $217.92 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price.
View analysts' price targets for Mirati Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Mirati Therapeutics' key executives?

Mirati Therapeutics' management team includes the following people:
  • Dr. Charles M. Baum, Pres, CEO & Director (Age 63, Pay $1.13M)
  • Mr. Daniel R. Faga, Chief Operating Officer (Age 41, Pay $1.16M)
  • Dr. James G. Christensen, Chief Scientific Officer (Age 53, Pay $820.05k)
  • Mr. Benjamin J. Hickey, Chief Commercial Officer (Age 45, Pay $798.32k)
  • Ms. Vickie S. Reed, Sr. VP & Chief Accounting Officer (Age 59)
  • Temre Johnson, Director of Investor Relations & Corp. Communications
  • Ms. Reena R. Desai, Gen. Counsel & Corp. Sec.
  • Ms. Kristin Gustafson, Chief HR Officer
  • Dr. Kelly Covello Ph.D., VP & Head of Medical Affairs
  • Mr. Ryan Asay, VP & Head of Corp. Affairs

Who are some of Mirati Therapeutics' key competitors?

What other stocks do shareholders of Mirati Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Square (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How do I buy shares of Mirati Therapeutics?

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mirati Therapeutics' stock price today?

One share of MRTX stock can currently be purchased for approximately $157.13.

How much money does Mirati Therapeutics make?

Mirati Therapeutics has a market capitalization of $8.08 billion and generates $13.40 million in revenue each year. The biotechnology company earns $-357,940,000.00 in net income (profit) each year or ($7.96) on an earnings per share basis.

How many employees does Mirati Therapeutics have?

Mirati Therapeutics employs 199 workers across the globe.

What is Mirati Therapeutics' official website?

The official website for Mirati Therapeutics is

Where are Mirati Therapeutics' headquarters?

Mirati Therapeutics is headquartered at 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121.

How can I contact Mirati Therapeutics?

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]

This page was last updated on 7/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.